Terms: = Germ cell tumor AND CDKN2A, CDK4I, 1029, ENSG00000147889, P42771, p14, CMM2, ARF, TP16, p16, MTS1, p19, p16INK4a, INK4a, CDKN2, p16INK4, p14ARF, MLM, INK4
2645 results:
1. [Methylthioadenosine phosphorylase and p16 as surrogate diagnostic markers for cdkn2a homozygous deletion in brain tumors].
Wang SN; Wang W; Zhang XW; Zhang YQ; Xiong YL; Liu L; Teng LH
Zhonghua Bing Li Xue Za Zhi; 2024 May; 53(5):439-445. PubMed ID: 38678323
[No Abstract] [Full Text] [Related]
2. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.
Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C
Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834
[TBL] [Abstract] [Full Text] [Related]
3. Metabologenomic characterization uncovers a clinically aggressive IDH mutant glioma subtype.
Nassiri F; Ajisebutu A; Patil V; Mamatjan Y; Liu J; Wang JZ; Voisin MR; Nejad R; Mansouri S; Karimi S; Chakravarthy A; Chen E; De Carvalho DD; Aldape K; Zadeh G
Acta Neuropathol; 2024 Apr; 147(1):68. PubMed ID: 38583102
[TBL] [Abstract] [Full Text] [Related]
4. OH2 oncolytic virus: A novel approach to glioblastoma intervention through direct targeting of tumor cells and augmentation of anti-tumor immune responses.
Zheng Y; Wang X; Ji Q; Fang A; Song L; Xu X; Lin Y; Peng Y; Yu J; Xie L; Chen F; Li X; Zhu S; Zhang B; Zhou L; Yu C; Wang Y; Wang L; Hu H; Zhang Z; Liu B; Wu Z; Li W
Cancer Lett; 2024 May; 589():216834. PubMed ID: 38537773
[TBL] [Abstract] [Full Text] [Related]
5. Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.
Sukniam K; Manaise HK; Popp K; Popp R; Gabriel E
Cells; 2024 Mar; 13(6):. PubMed ID: 38534309
[TBL] [Abstract] [Full Text] [Related]
6. p53 regulates diverse tissue-specific outcomes to endogenous DNA damage in mice.
Hill RJ; Bona N; Smink J; Webb HK; Crisp A; Garaycoechea JI; Crossan GP
Nat Commun; 2024 Mar; 15(1):2518. PubMed ID: 38514641
[TBL] [Abstract] [Full Text] [Related]
7. High-Grade Astrocytoma with Piloid Features: A Dual Institutional Review of Imaging Findings of a Novel Entity.
Soni N; Agarwal A; Ajmera P; Mehta P; Gupta V; Vibhute M; Gubbiotti M; Mark IT; Messina SA; Mohan S; Bathla G
AJNR Am J Neuroradiol; 2024 Apr; 45(4):468-474. PubMed ID: 38485198
[TBL] [Abstract] [Full Text] [Related]
8. Glioblastoma Therapy: Past, Present and Future.
Obrador E; Moreno-Murciano P; Oriol-Caballo M; López-Blanch R; Pineda B; Gutiérrez-Arroyo JL; Loras A; Gonzalez-Bonet LG; Martinez-Cadenas C; Estrela JM; Marqués-Torrejón MÁ
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473776
[TBL] [Abstract] [Full Text] [Related]
9. cdkn2a promoter methylation enhances self-renewal of glioblastoma stem cells and confers resistance to carmustine.
Wang J; Xi YF; Zhao Q; Guo JH; Zhang Z; Zhang MB; Chang J; Wu YQ; Su W
Mol Biol Rep; 2024 Mar; 51(1):385. PubMed ID: 38438773
[TBL] [Abstract] [Full Text] [Related]
10. METTL14-Mediated m6a Modification of cdkn2a Promotes the Development of Retinoblastoma by Inhibiting the p53 Pathway.
Chen J; Zeng B
Crit Rev Immunol; 2024; 44(3):89-98. PubMed ID: 38421707
[TBL] [Abstract] [Full Text] [Related]
11. Restrospective reappraisal of the prognostic classification of spitzoid melanocytic neoplasms after BRAF and NRAS mutation characterisation: a single institution experience.
Moysset I; Castrejon N; Garcia-Herrera A; Castillo P; Marginet M; Teixido C; Podlipnik S; Albero-Gonzalez R; Montironi C; Navarro J; Rovira C; Puig S; Carrera C; Alos L
Histopathology; 2024 Jun; 84(7):1154-1166. PubMed ID: 38409889
[TBL] [Abstract] [Full Text] [Related]
12. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.
Dobre EG; Nichita L; Popp C; Zurac S; Neagu M
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396984
[TBL] [Abstract] [Full Text] [Related]
13. Looking through the imaging perspective: the importance of imaging necrosis in glioma diagnosis and prognostic prediction - single centre experience.
Ma H; Zeng S; Xie D; Zeng W; Huang Y; Mazu L; Zhu N; Yang Z; Chu J; Zhao J
Radiol Oncol; 2024 Mar; 58(1):23-32. PubMed ID: 38378035
[TBL] [Abstract] [Full Text] [Related]
14. Clinical and molecular study of radiation-induced gliomas.
Trkova K; Sumerauer D; Bubenikova A; Krskova L; Vicha A; Koblizek M; Zamecnik J; Jurasek B; Kyncl M; Malinova B; Ondrova B; Jones DTW; Sill M; Strnadova M; Stolova L; Misove A; Benes V; Zapotocky M
Sci Rep; 2024 Feb; 14(1):3118. PubMed ID: 38326438
[TBL] [Abstract] [Full Text] [Related]
15. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract] [Full Text] [Related]
16. Artificial Intelligence Imaging for Predicting High-risk Molecular Markers of Gliomas.
Liang Q; Jing H; Shao Y; Wang Y; Zhang H
Clin Neuroradiol; 2024 Mar; 34(1):33-43. PubMed ID: 38277059
[TBL] [Abstract] [Full Text] [Related]
17. GlioPredictor: a deep learning model for identification of high-risk adult IDH-mutant glioma towards adjuvant treatment planning.
Zheng S; Rammohan N; Sita T; Teo PT; Wu Y; Lesniak M; Sachdev S; Thomas TO
Sci Rep; 2024 Jan; 14(1):2126. PubMed ID: 38267516
[TBL] [Abstract] [Full Text] [Related]
18. cdkn2a/B deletion in IDH-mutant astrocytomas: An evaluation by Fluorescence in-situ hybridization.
Ranade M; Epari S; Shetty O; Dhanavade S; Chavan S; Sahay A; Sahu A; Shetty P; Moiyadi A; Singh V; Dasgupta A; Chatterjee A; Kannan S; Gupta T
J Neurooncol; 2024 Mar; 167(1):189-198. PubMed ID: 38265748
[TBL] [Abstract] [Full Text] [Related]
19. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
[TBL] [Abstract] [Full Text] [Related]
20. Reliable detection of genetic alterations in cyst fluid DNA for the diagnosis of brain tumors.
On J; Natsumeda M; Takahashi H; Koyama A; Shibuma S; Shibata N; Watanabe J; Saito S; Kanemaru Y; Tsukamoto Y; Okada M; Ogura R; Eda T; Tada M; Shimizu H; Adachi JI; Mishima K; Nishikawa R; Kakita A; Oishi M
J Neurooncol; 2024 Jan; 166(2):273-282. PubMed ID: 38227143
[TBL] [Abstract] [Full Text] [Related]
[Next]
